PFS and OS according to MRD status after transplantation and bulky disease at diagnosis. MRD status after ASCT correlates to PFS (A) and OS (B). Achievement of molecular remission after ASCT strongly predicts improved PFS, with median PFS of 92 months for the MRD-negative group compared with 21 months in the MRD-positive group (P < .001). Bulky disease at diagnosis was associated with adverse PFS (C) and OS (D).